Adverse events (grade ≥ 3) · previously untreated patients with mRCC
Interferon‐α combined with targeted therapies may leads to higher adverse events (grade ≥ 3) compared with standard targeted therapy (low certainty).
1 finding from 1 review
Adverse events (grade ≥ 3) · previously untreated patients with mRCC
Interferon‐α alone probably leads to lower adverse events (grade ≥ 3) compared with interferon‐α plus bevacizumab (moderate certainty).
1 finding from 1 review
Adverse events (grade ≥ 3) · previously untreated patients with mRCC
Interferon‐α plus bevacizumab showed no clear difference in adverse events (grade ≥ 3) compared with standard targeted therapies (low certainty).
1 finding from 1 review
Adverse events (grade ≥ 3) · previously untreated patients with mRCC
Vaccine treatment showed no clear difference in adverse events (grade ≥ 3) compared with standard therapies (low certainty).
1 finding from 1 review
Adverse events (grade ≥ 3) · previously treated patients with mRCC
Targeted immunotherapy alone probably leads to lower adverse events (grade ≥ 3) compared with standard targeted therapies (moderate certainty).
1 finding from 1 review
Adverse events (grade ≥ 3) · previously untreated patients with mRCC
Interferon‐α alone may leads to higher adverse events (grade ≥ 3) compared with standard targeted therapies (sunitinib or temsirolimus) (low certainty).
1 finding from 1 review
Serious adverse events (Grade 3 or 4) · Previous treated and treatment‐naïve (54%) metastatic renal cell carcinoma (clear cell type)
Pazopanib leads to higher serious adverse events (Grade 3 or 4) compared with placebo (targeted agent versus placebo) (high certainty).
1 finding from 1 review
Intervention not reported
Adverse events (AEs) (grade 3 or 4) ‐ Network included 19 pairwise comparisons ‐ Mean risk with SUN across trials3 in this network: 70.6% · people with a confirmed diagnosis of advanced renal cell carcinoma (combined risk groups) without previous systemic anticancer therapy
1 finding from 1 review